The Division of Clinical Haematology, in partnership with the UCT Clinical Research Centre, runs various clinical trials at Groote Schuur Hospital. Our collaborative efforts aim to advance treatments for various diseases and provide patients with the opportunity to access novel treatments that are in development.
The current clinical trials investigate the treatment of haematological malignancies including chronic lymphocytic leukaemia (CLL), small lymphocytic lymphoma (SLL), multiple myeloma (MM), follicular lymphoma (FL), and diffuse large B-cell lymphoma (DLBCL). We have previous experience with various phases of clinical trials in both benign and malignant haematological conditions. Please contact Dr. Fiona Watt (fiona.watt@uct.ac.za) or Dr. Brigid McMillan (brigid.mcmillan@uct.ac.za) if you would like any further information.
Trials currently recruiting new patients:
1. MK1026-008 (BELLWAVE-008): A Phase 3, Randomized Study to Compare the Efficacy and Safety of Nemtabrutinib Versus Chemoimmunotherapy for Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Without TP53 Aberrations
2. MK1026-010 (BELLWAVE-010): A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Nemtabrutinib (MK-1026) Plus Venetoclax Versus Venetoclax Plus Rituximab in Participants with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Following at Least 1 Prior Therapy.
3. MK1026-011 (BELLWAVE-011): A Study of Nemtabrutinib Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma
Trials in the start-up phase:
1. BGB-3111-308: A Phase 3 Randomized, Open-Label, Multicenter Study of Zanubrutinib (BGB 3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
2. M22-003: A Phase 3, Multicenter, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of Epcoritamab + Rituximab and Lenalidomide (R2) Compared to Chemoimmunotherapy in Previously Untreated Follicular Lymphoma
3. MK2140-010: A Randomized, Open-Label, Multicenter, Phase 3 Study of Zilovertamab Vedotin (MK-2140) in Combination With R-CHP Versus R-CHOP in Participants With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL)
4. CA057-001: A Phase 3, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing Mezigdomide (CC-92480), Bortezomib and Dexamethasone (MeziVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM) - Successor-1
5. 214828: A Phase 3, randomized, open-label study of belantamab mafodotin administered in combination with lenalidomide and dexamethasone (BRd) versus daratumumab, lenalidomide, and dexamethasone (DRd) in participants with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation (TI-NDMM) - DREAMM-10
6. CT-P44: A Double-Blind, Randomized, Active-Controlled, Parallel-group, Phase 1/3 Study to Compare Pharmacokinetics, Efficacy and Safety of subcutaneous CT-P44 and Darzalex Faspro in combination with lenalidomide and dexamethasone in Patients with Refractory or Relapsed Multiple Myeloma